GENB

Generate Biomedicines

16.12

+0.13+0.81%

After Hours: 16.06 -0.06 -0.37%19:30 08/21 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE20.00/20.38

TODAY RANGE15.93-20.14

VOL3.85M

MARKET CAP2.07B

52 WEEK RANGE11.00-22.67

AVG VOL (3M)950.86K

% TURNOVER2.98%

TURNOVER--

P/E (TTM)-10.1439

% RANGE20.63%

EPS(TTM)-1.5911

P/E(FORWARD)-6.9196

P/B4.540

BVPS3.555

DIVIDEND--

P/S64.51

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP1.75B

SHARES OUTSTANDING128.35M

NEXT EARNINGS--

FREE FLOAT108.60M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

Benzinga·11h ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
TipRanks·14h ago
Generate Biomedicines falls -11.0%
NASDAQ·19h ago
Biotech Stocks At 52-Week Highs - GENB +15%, BDSX +10%, CDNA +6%, CPIX +10%, CRDL +7%
TipRanks·1d ago
Generate Biomedicines rises 17.7%
TipRanks·08/17 12:57
Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)
Seeking Alpha·08/14 21:04
Nvidia discloses big stake in SpaceX in Q2 moves
Seeking Alpha·08/10 23:22
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
TipRanks·08/07 12:09
Piper Sandler Remains a Buy on Generate Biomedicines, Inc. (GENB)
Seeking Alpha·08/06 17:17
Generate Biomedicines, Inc. reports Q2 results
TipRanks·08/06 12:06
Generate Biomedicines reports Q2 EPS (52c), consensus (49c)
Dow Jones·08/06 11:15
*Generate Biomedicines 2Q Loss/Shr 52c >GENB
Dow Jones·08/06 11:15
*Generate Biomedicines 2Q Rev $6.31M >GENB
Dow Jones·08/06 11:15
*Generate Biomedicines 2Q Loss $67.3M >GENB
Dow Jones·08/06 11:00
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Dow Jones·08/06 11:00
Press Release: Generate Biomedicines Inc. Reports -2-

Same Industry

Name/Symbol

Change%

Price

Thermo Fishr Sci

TMO

+0.27%

629.27

WAT

DHR

FLGT

Resmed

RMD

+1.78%

236.59

CHKP

ABMD

GEHC

ISRG

VEEV

RVTY

INMD

ATHN

Bruker Corp

BRKR

-4.33%

56.98

VAR

ITGR

HOLX

QDEL

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.